ARTV Stock Forecast 2025-2026
Distance to ARTV Price Targets
ARTV Price Momentum
10 Quality Stocks Worth Considering Now
Researching Artiva (ARTV) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ARTV and similar high-potential opportunities.
Latest ARTV Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, ARTV has a bullish consensus with a median price target of $20.00 (ranging from $18.00 to $23.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $3.64, the median forecast implies a 449.5% upside. This outlook is supported by 6 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Gil Blum at Needham, projecting a 531.9% upside. Conversely, the most conservative target is provided by Martin Fan at Wedbush, suggesting a 394.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ARTV Analyst Ratings
ARTV Price Target Range
Latest ARTV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ARTV.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 26, 2025 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $20.00 |
| Mar 25, 2025 | Cantor Fitzgerald | Josh Schimmer | Overweight | Maintains | $20.00 |
| Mar 25, 2025 | Wedbush | Martin Fan | Outperform | Reiterates | $18.00 |
| Mar 25, 2025 | Needham | Gil Blum | Buy | Reiterates | $23.00 |
| Dec 30, 2024 | HC Wainwright & Co. | Edward White | Buy | Initiates | $20.00 |
| Nov 13, 2024 | Needham | Gil Blum | Buy | Reiterates | $23.00 |
| Aug 30, 2024 | Needham | Gil Blum | Buy | Reiterates | $23.00 |
| Aug 13, 2024 | Cantor Fitzgerald | Josh Schimmer | Overweight | Initiates | $23.00 |
| Aug 13, 2024 | Needham | Gil Blum | Buy | Initiates | $23.00 |
| Aug 13, 2024 | TD Cowen | Tyler Van Buren | Buy | Initiates | $0.00 |
| Aug 13, 2024 | Wedbush | David Nierengarten | Outperform | Initiates | $18.00 |
| Aug 13, 2024 | Jefferies | Kelly Shi | Buy | Initiates | $21.00 |
Artiva Biotherapeutics Inc. (ARTV) Competitors
The following stocks are similar to Artiva based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Artiva Biotherapeutics Inc. (ARTV) Financial Data
Artiva Biotherapeutics Inc. has a market capitalization of $96.91M with a P/E ratio of -0.6x. The company generates $251,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -100.0% quarter-over-quarter, while maintaining an operating margin of -26,805.6% and return on equity of -54.2%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Artiva Biotherapeutics Inc. (ARTV) Business Model
About Artiva Biotherapeutics Inc.
Develops NK cell therapies for cancer treatment.
Artiva Biotherapeutics generates revenue through the development and commercialization of innovative natural killer (NK) cell therapies aimed at treating cancer. By utilizing proprietary manufacturing processes, the company creates scalable, off-the-shelf therapeutic products that can be widely distributed in the oncology market.
With a focus on advancing immunotherapy, Artiva is strategically positioned in the biotechnology sector, which is experiencing significant growth due to increasing interest in biologics and immune-oncology. The company is dedicated to enhancing cancer treatment accessibility and efficacy, making it a key player in the ongoing evolution of cancer therapies.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
82
CEO
Dr. Fred Aslan M.D.
Country
United States
IPO Year
2024
Website
www.artivabio.comArtiva Biotherapeutics Inc. (ARTV) Latest News & Analysis
Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights
3 days agoArtiva Biotherapeutics plans to present updated data on AlloNK® in 2025, with a strong cash position of $185.4 million expected to fund operations through 2026.
The news highlights Artiva's promising advancements in cell therapies, strong financial position, and leadership enhancements, which may signal growth potential and increased investor confidence.
Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
1 month agoArtiva Biotherapeutics (Nasdaq: ARTV) will present at the TD Cowen Health Care Conference on March 5, 2025, at 2:30 p.m. EST in Boston, focusing on cell therapies for autoimmune diseases and cancers.
Artiva Biotherapeutics' participation in a major healthcare conference could signal potential growth and investor interest, impacting stock performance and market perception.
Artiva Biotherapeutics appointed Dr. Dan Baker to its Board of Directors. He has over 20 years of drug development experience, including roles at Cue Biopharma and Johnson & Johnson.
The appointment of Dr. Baker to Artiva Biotherapeutics' Board enhances credibility and strategic insight, potentially accelerating drug development and improving investor confidence in the company’s future.
Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
4 months agoAlloKine has expanded its Board of Directors by appointing Dr. Alison Moore, who will contribute her expertise in cell therapy and manufacturing to enhance AlloNK® for autoimmune diseases.
The appointment of Dr. Alison Moore enhances AlloNK®'s development potential in autoimmune diseases, signaling growth prospects and strategic positioning for investors.
Artiva Biotherapeutics (Nasdaq: ARTV) will participate in a fireside chat at the Jefferies London Healthcare Conference on November 20, 2024, at 3:30 p.m. GMT.
Artiva Biotherapeutics' participation in a prominent healthcare conference signals potential visibility and interest in its innovations, which could affect stock performance and investor sentiment.
Artiva Biotherapeutics appointed Alison Moore, Ph.D., as an independent director to its Board, enhancing leadership in developing cell therapies for autoimmune diseases and cancers.
The appointment of Dr. Alison Moore to Artiva's Board could signal strategic growth and expertise, potentially enhancing the company's credibility and future prospects in biotech.
Frequently Asked Questions About ARTV Stock
What is Artiva Biotherapeutics Inc.'s (ARTV) stock forecast for 2025?
Based on our analysis of 7 Wall Street analysts, Artiva Biotherapeutics Inc. (ARTV) has a median price target of $20.00. The highest price target is $23.00 and the lowest is $18.00.
Is ARTV stock a good investment in 2025?
According to current analyst ratings, ARTV has 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.64. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ARTV stock?
Wall Street analysts predict ARTV stock could reach $20.00 in the next 12 months. This represents a 449.5% increase from the current price of $3.64. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Artiva Biotherapeutics Inc.'s business model?
Artiva Biotherapeutics generates revenue through the development and commercialization of innovative natural killer (NK) cell therapies aimed at treating cancer. By utilizing proprietary manufacturing processes, the company creates scalable, off-the-shelf therapeutic products that can be widely distributed in the oncology market.
What is the highest forecasted price for ARTV Artiva Biotherapeutics Inc.?
The highest price target for ARTV is $23.00 from Gil Blum at Needham, which represents a 531.9% increase from the current price of $3.64.
What is the lowest forecasted price for ARTV Artiva Biotherapeutics Inc.?
The lowest price target for ARTV is $18.00 from Martin Fan at Wedbush, which represents a 394.5% increase from the current price of $3.64.
What is the overall ARTV consensus from analysts for Artiva Biotherapeutics Inc.?
The overall analyst consensus for ARTV is bullish. Out of 7 Wall Street analysts, 6 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $20.00.
How accurate are ARTV stock price projections?
Stock price projections, including those for Artiva Biotherapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
